A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
As used herein, the terms “Company,” “Cencora,” “we,” “us,” or “our” refer to Cencora, Inc., a Delaware corporation. Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 325.8B | 321.3B | 294.0B | 262.2B | 238.6B | 214.0B |
| Net Income | 1.6B | 1.6B | 1.5B | 1.7B | 1.7B | 1.5B |
| EPS | $8.33 | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 |
| Free Cash Flow | 3.6B | 3.2B | 3.0B | 3.5B | 2.2B | 2.2B |
| ROIC | 28.1% | 316.9% | 2.5% | 245.1% | 3.2% | 77.4% |
| Gross Margin | 3.7% | 3.6% | 3.4% | 3.4% | 3.5% | 3.2% |
| Debt/Equity | 4.33 | 5.16 | 7.69 | 10.40 | -32.02 | 31.27 |
| Dividends/Share | $2.33 | $2.20 | $2.04 | $1.94 | $1.84 | $1.76 |
| Operating Income | 2.7B | 2.6B | 2.2B | 2.3B | 2.4B | 2.4B |
| Operating Margin | 0.8% | 0.8% | 0.7% | 0.9% | 1.0% | 1.1% |
| ROE | 85.2% | 144.3% | 233.6% | 334.3% | - | 689.5% |
| Shares Outstanding | 195M | 195M | 200M | 205M | 211M | 208M |
Cencora, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Cencora, Inc. trades at 38.3x trailing earnings, compared to its 15-year median P/E of 16.7x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 17.2x vs a median of 11.7x. The company's 5-year average ROIC is 27.7% with a gross margin of 3.4%. Total shareholder yield (dividends) is 0.8%. At current prices, the estimated annualized return to fair value is +11.1%.
Cencora, Inc. (COR) has a current P/E ratio of 38.3, compared to its historical median P/E of 16.7. The stock is currently considered Expensive based on its historical valuation range.
Cencora, Inc. (COR) has a 5-year average return on invested capital (ROIC) of 27.7%. This indicates strong capital allocation and a potential competitive advantage.
Cencora, Inc. (COR) has a market capitalization of $62.1B. It is classified as a large-cap stock.
Yes, Cencora, Inc. (COR) pays a dividend with a trailing twelve-month yield of 0.73%. The company also returns capital through share buybacks, with a buyback yield of 0.08%.
Based on historical P/E analysis, Cencora, Inc. (COR) appears expensive. The current P/E of 38.3 is 130% above its historical median of 16.7. The estimated fair value CAGR (P/E method) is 11.0%.
Cencora, Inc. (COR) operates in the Wholesale-Drugs, Proprietaries & Druggists' Sundries industry, within the Consumer Defensive sector.
Cencora, Inc. (COR) reported annual revenue of $321.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Cencora, Inc. (COR) has a net profit margin of 0.5%. This is a modest margin.
Cencora, Inc. (COR) generated $3.2 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Cencora, Inc. (COR) has a debt-to-equity ratio of 5.16. This indicates higher leverage, which may increase financial risk.
Cencora, Inc. (COR) reported earnings per share (EPS) of $7.96 in its most recent fiscal year.
Cencora, Inc. (COR) has a return on equity (ROE) of 144.3%. This indicates the company generates strong returns for shareholders.
Cencora, Inc. (COR) has a 5-year average gross margin of 3.4%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 19 years of financial data for Cencora, Inc. (COR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cencora, Inc. (COR) has a book value per share of $7.72, based on its most recent annual SEC filing.